Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nexavar Extension Program for Metastatic Neoplasms
NCT00657254Phase 2Completed
- Sponsor
- Bayer
- Start
- Dec 2002
- Primary completion
- Jun 2005
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in Neoplasm, sponsored by Bayer. Primary endpoint: Overall Survival. Started Dec 2002; status: completed.
02
Drugs
sorafenib
03
Conditions
Neoplasm
Beyond the preview
Go deeper on NCT00657254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00657254.